ClinicaliQ Trial Snapshot
- Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer — Active Not Recruiting • Phase I / Phase II • Oncology • NCT03436485.
- ODM-208 showed acceptable safety in advanced prostate cancer patients, supporting further development of this new treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer. Conditions: Prostate Cancer Metastatic Interventions: ODM-208, Midazolam Lead Sponsor: Orion Corporation, Orion Pharma Planned Enrollment: 204 participants